105 related articles for article (PubMed ID: 8072603)
1. Sexual influence on bone metabolism in uremic patients on regular dialytic treatment.
Luisetto G; Bertoli M
Nephron; 1994; 67(2):150-7. PubMed ID: 8072603
[TBL] [Abstract][Full Text] [Related]
2. [Determination of bone mineral content and correlations with calciotropic hormones in periodic hemodialysis patients].
Anelli F; De Maio P; Girardi V; Papagni S; Rossi G; Cantatore FP; Carrozzo M
Minerva Urol Nefrol; 1992; 44(4):265-73. PubMed ID: 1299008
[TBL] [Abstract][Full Text] [Related]
3. Gastric acid secretion, calcitonin and secondary hyperparathyroidism in uremic patients undergoing regular dialysis therapy (RDT).
Antonucci F; Vezzadini P; Cecchettin M; Bonora G; Adami A; Compiano U; Feder G
Int J Artif Organs; 1978 Nov; 1(6):260-5. PubMed ID: 738794
[TBL] [Abstract][Full Text] [Related]
4. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
5. Long-term effects of intravenous 1 alpha (OH)D3 combined with CaCO3 and low-calcium dialysis on secondary hyperparathyroidism and biochemical bone markers in patients on chronic hemodialysis.
Brandi L; Daugaard H; Nielsen PK; Jensen LT; Egsmose C; Olgaard K
Nephron; 1996; 74(1):89-103. PubMed ID: 8883025
[TBL] [Abstract][Full Text] [Related]
6. Influence of sevelamer hydrochloride on serum concentration of whole (1-84) and N-terminally truncated (7-84) parathyroid hormone fragments in hemodialysis uremic patients.
Chudek J; Piecha G; Kokot F; Wiecek A
J Nephrol; 2003; 16(5):710-5. PubMed ID: 14733418
[TBL] [Abstract][Full Text] [Related]
7. Changes of bone markers during long-term intravenous calcitriol therapy in maintenance dialysis patients.
Lee SH; Huang TS; Hsieh SJ
Miner Electrolyte Metab; 1996; 22(4):219-23. PubMed ID: 8807625
[TBL] [Abstract][Full Text] [Related]
8. Role of persistent amenorrhea in bone mineral metabolism of young hemodialyzed women.
Weisinger JR; Gonzalez L; Alvarez H; Hernandez E; Carlini RG; Capriles F; Cerviño M; Martinis R; Paz-Martínez V; Bellorín-Font E
Kidney Int; 2000 Jul; 58(1):331-5. PubMed ID: 10886579
[TBL] [Abstract][Full Text] [Related]
9. [PTH and bone metabolism in chronic dialysis patients].
Fukagawa M; Kazama J; Shigematsu T
Rinsho Byori; 2001 Mar; 49(3):236-8. PubMed ID: 11307321
[TBL] [Abstract][Full Text] [Related]
10. Influence of sex and age on biochemical bone metabolism parameters.
Resch H; Pietschmann P; Kudlacek S; Woloszczuk W; Krexner E; Bernecker P; Willvonseder R
Miner Electrolyte Metab; 1994; 20(3):117-21. PubMed ID: 7815999
[TBL] [Abstract][Full Text] [Related]
11. [Effect of salmon calcitonin on bone mineral density and calcium-phosphate metabolism in chronic hemodialysis patients with secondary hyperparathyroidism].
Matuszkiewicz-Rowińska J; Niemczyk S; Przedlacki J; Puka J; Switalski M; Ostrowski K
Pol Arch Med Wewn; 2004 Jul; 112(1):797-803. PubMed ID: 15526839
[TBL] [Abstract][Full Text] [Related]
12. Serum and dialysate osteocalcin levels in hemodialysis and peritoneal dialysis patients and after renal transplantation.
Epstein S; Traberg H; Raja R; Poser J
J Clin Endocrinol Metab; 1985 Jun; 60(6):1253-6. PubMed ID: 3889031
[TBL] [Abstract][Full Text] [Related]
13. An evaluation of 1-84 PTH measurement in relation to bone alkaline phosphatase and bone Gla protein in hemodialysis patients.
Miwa N; Nitta K; Kimata N; Watanabe Y; Suzuki K; Kawashima A; Haga M; Watanabe R; Aoki T; Akiba T; Nihei H
Nephron Clin Pract; 2003; 94(2):c29-32. PubMed ID: 12845234
[TBL] [Abstract][Full Text] [Related]
14. Salmon calcitonin in prevention of osteoporosis in maintenance dialysis patients.
Wang SX; Li H
Chin Med J (Engl); 2008 Jul; 121(14):1280-4. PubMed ID: 18713548
[TBL] [Abstract][Full Text] [Related]
15. Influence of calcium infusion on calcitonin and parathyroid hormone concentrations in normal and hemodialyzed subjects.
Isaac R; Nivez MP; Piamba G; Fillastre JP; Ardaillou R
Clin Nephrol; 1975 Jan; 3(1):14-7. PubMed ID: 1126058
[TBL] [Abstract][Full Text] [Related]
16. Effect of aluminium on the development of hyperparathyroidism and bone disease in the azotaemic rat.
Felsenfeld AJ; Machado L; Bover J; Trinidad P; Rodriguez M
Nephrol Dial Transplant; 1993; 8(4):325-34. PubMed ID: 8390007
[TBL] [Abstract][Full Text] [Related]
17. Combined hemodialysis-hemoperfusion in the treatment of secondary hyperparathyroidism of uremic patients.
Morachiello P; Landini S; Fracasso A; Righetto F; Scanferla F; Toffoletto P; Genchi R; Bazzato G
Blood Purif; 1991; 9(3):148-52. PubMed ID: 1801857
[TBL] [Abstract][Full Text] [Related]
18. Biochemical parameters associated with low bone density in healthy men and women.
Sherman SS; Tobin JD; Hollis BW; Gundberg CM; Roy TA; Plato CC
J Bone Miner Res; 1992 Oct; 7(10):1123-30. PubMed ID: 1456082
[TBL] [Abstract][Full Text] [Related]
19. Effects of 22-oxacalcitriol and calcitriol on PTH secretion and bone mineral metabolism in a crossover trial in hemodialysis patients with secondary hyperparathyroidism.
Ogata H; Koiwa F; Shishido K; Takahashi K; Ito H; Kinugasa E; Taguchi S
Ther Apher Dial; 2007 Jun; 11(3):202-9. PubMed ID: 17498002
[TBL] [Abstract][Full Text] [Related]
20. A trial of calcitonin therapy in renal osteodystrophy.
Delano BG; Baker R; Gardner B; Wallach S
Nephron; 1973; 11(5):287-93. PubMed ID: 4753519
[No Abstract] [Full Text] [Related]
[Next] [New Search]
